Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
Executive Changes

Orexigen Therapeutics Founder Resigns From Board

Executive Summary

Obesity specialist Orexigen Therapeutics Inc. has announced that its co-founder and former chair, Eckard Weber, has stepped down from the board of directors. Weber, who co-founded the company with Michael Cowley in 2002, was chair from 2002 until earlier this year, and also served as interim president and CEO between November 2008 and March 2009. Weber is also a partner at Domain Associates, LLC., a venture capital firm which owns approximately 11.3 million shares of Orexigen common stock.

Table

View full table

Topics

Tags:
Executive Changes
Latest Headlines

‘It’s Not About Me’ – AstraZeneca’s Soriot Says His Pay Rise Will Help European Pharma

Executives On The Move: Three New CEOs Among This Week's Changes

Sanofi To Pursue Smart M&A Pacts And Stick With Early-Stage Oncology R&D

Xaira Launches With $1bn-Plus And End-To-End AI Strategy

See All
UsernamePublicRestriction

Register

SC065337

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By